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Abstract
Background: Tuberculosis (TB) in both animals and humans is caused by Mycobacterium tuberculosis complex
(MTBC) primarily transmitted by inhalation of aerosolized droplets containing the organism. Multi-drug resistance
(MDR) and extensive drug resistance (XDR) are evolutionary features of Mycobacterium tuberculosis to subvert the
antibiotic regimes in place. The heavy burden of TB worsened by HIV endemic in South Africa motivated for the
investigation of MTBC prevalence among TB patients in Port Elizabeth and the amplification and sequencing of the
DNA amplicons known to confer resistance to TB drugs.
Methods: Three thousand eight hundred and ten (3810) sputum specimens were processed and DNA was isolated
from sputum specimens collected from different hospitals and health care places in the Eastern Cape Province,
South Africa. DNA was amplified using the Seeplex® MTB Nested ACE detection assay. The agar-dilution proportion
method was used to perform drug-sensitivity testing using 7H10 Middlebrook medium. Target genes known to
confer resistance to first and second-line drugs were amplified and the amplicons sequenced.
Results: One hundred and ninety (5%) DNA samples tested positive for MTBC and from the resistant profiles of the
190 positive samples, we noted that multidrug-resistant TB was identified in 189 (99.5%) with 190 (100%) patients
infected with MTB resistant to isoniazid and 189 (99.5%) having MTB resistant to rifampicin. Other percentages of
drug resistance observed including 40% pre-XDR and 60% of XDR.
Conclusion: This study provides valuable data on the different kinds of mutations occurring at various target loci in
resistant MTBC strains isolated from samples obtained from the Eastern Cape Province. The results obtained reveal a
high incidence of MDR amongst the positive samples from Eastern Cape Province, South Africa.
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Background
The Mycobacterium tuberculosis Complex (MTBC) con-
sists of nine bacterial species that cause tuberculosis (TB)
in mammals, including human beings [1]. MTBC results
in substantial economic losses in cattle herds and humans
as it is usually found in the more economically active
humans [2]. Tuberculosis is a major public health concern
and a third of the world’s population is infected with some
members of MTBC [1]. South Africa is a country with
high incidence of TB, there were 550 cases per 100 000
population in 2003, 718 case per 100 000 population in
2004 [3,4] and 600 cases per 100 000 population in 2005
[5]. The country had one of the worst recorded epidemics
in the world in 2008 caused by the rising rates of HIV and
the emergence of multidrug resistant TB [6]. The country
is divided into nine provinces and among them the Eastern
Cape has 80% of TB cases in South Africa [7]. The Eastern
Cape is one of the poorest Provinces in South Africa and
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because of its poverty the spread of TB is enhanced [8].
Most people take TB as a disease of the past decade caused
by strains that cannot be treated with existing drugs; this
disease has turned to be one of the world’s most pressing
health problems [6].
Resistance of the organisms to TB drugs is a major pub-
lic health problem that threatens the progress made in TB
control worldwide. Drug resistance arises due to improper
use of antibiotics in chemotherapy of drug susceptible
organisms [6]. Multidrug-resistance TB (MDR-TB) is re-
sistant to the two most commonly used drugs (isoniazid
and rifampicin) in the common four drug regimen [9]. In
2010, the World Health Organization (WHO) estimated
that there were globally 290 000 cases of MDR-TB among
cases of pulmonary TB that were reported [10]. There
have been 1.8% increases in MDR-TB cases in South
Africa. There are several factors that contribute to the de-
velopment of MDR-TB, such as poor adherence of pa-
tients to first line anti-TB drugs, dosage and duration of
treatment, inappropriate treatment regiments and non-
compliance to national guidelines and TB protocol by TB
clinicians [11].
Inappropriate use of second line drugs used in the
treatment of TB leads to amplification of resistance and
development of XDR-TB [10]. Extensively drug resist-
ance TB (XDR-TB) is the TB resistant to any fluoroquino-
lone and at least one of the injectable drugs (capreomycin,
kanamycin and amikacin) in addition to isoniazid and
rifampicin. Several methods have been used to identify
MTBC, including culture and biochemical tests such as
acid-fast smears and sputum cultures. The diagnosis of
TB includes history, physical examination and radiological
findings in lung apices. Acid-fast smears and cultures of
sputum are also required [12]. This study aimed at using a
multiplex PCR targeting two genes (mpb64 coding for im-
munogenic secretory protein specific for Mycobacterium
tuberculosis complex and IS6110 insertion element found
exclusively within the members of the MTBC) for the
detection of MTBC in sputum samples obtained from
Eastern Cape Province and determination drug resistance
using sequencing of the DNA amplicons known to confer
resistance to TB drugs.
Methods
Sample collection
Three thousand eight hundred and ten sputum speci-
mens in the Eastern Cape Province were collected from
different hospitals and clinics from patients that showed
clinical signs of TB and transported to the microbiology
laboratory at Fort Hare University, South Africa for cul-
ture over a period of 24 months from January 2012 to
2013 December. Biodata including age (0–20; 21–40;
41–60 and 60 years and above) and gender of the patients
were also collected.
Bacteriological procedure
The bacteriological procedure was done as outlined by
Balows et al. [13]. NaOH (4%) was used to kill any other
contaminants in this procedure. Two Lowenstein-Jensen
(LJ) slants were inoculated and incubated at 37°C for
6–8 weeks. A smear was prepared from each of the proc-
essed samples on a grease-free slide and stained by car-
bol fuschin using the Ziehl_Neelsen technique. Slides
were checked for AFB under a microscope. Mycoba-
teria were isolated from sputum. Isolation and identifica-
tion of mycobacteria was carried out by the Microbiology
service of each hospital using acid-fast staining (AFB).
Drug susceptibility
Antibiotic susceptibility profiles were done at the National
Health Laboratory Services in Port Elizabeth. Several
spade-full of growth were scraped from LJ slants, trans-
ferred to a sterile screw-cap tube containing glass beads
and 3 ml normal saline (0.85%) and mixed well on a
vortex mixer. Turbidity was matched against McFarland
standard no. 1. Inoculum (100 μl) was added to each
plate, containing 5 ml 7H10 Middlebrook medium with
drug in each quadrant. M. tuberculosis strain H37Rv
was used as control in all sets of experiments. The inocu-
lated plates were incubated at 37°C in an atmosphere of
10% CO2.
The agar-dilution proportion method was performed
according to Balows et al. [13]. Lyophilized drugs were
reconstituted aseptically in water. The stock was diluted
in such a manner that a 5 μl aliquot contained the
requisite amount of each drug. The drug concentrations
used in this study were isoniazid (1 μg ml-1) Rifampicin
(5 μg ml-1), Streptomycin (10 μg ml-1), Ethambutol
(10 μg ml-1), Ethionamide (5 μg ml-1), ofloxacin (2 μg ml-1),
Amikacin (6 μg ml-1) and capreomycin (40 μg ml-1). Re-
sults were recorded after 3 weeks. Each drug-sensitivity
test was carried out at least three times and the average
was recorded.
Identification of MTBC species using Seeplex® MTB nested
ACE detection assay
The Seeplex® MTB Nested ACE detection assay (Seegene
Inc, Korea) was carried according to the manufacturer’s
instructions using a thermal cycler (Bio-Rad, South
Africa). The assay is a multiplex PCR involving the
first PCR (1 cycle at 94°C for 15 min; 40 cycles at
94°C for 30 s, 60°C for 30 s, 72°C for 30 s; 1 cycle at
72°C for 5 min) and a nested PCR (1 cycle at 94°C
for 15 min; 30 cycles at 94°C for 30 s, 62°C for 30 s,
72°C for 30 s; 1 cycle at 72°C for 5 min). The ampli-
cons were separated on 2% agarose gel electrophoresis,
at 100 V for 90 minutes using TBE buffer pH 8.3. The gel
was thereafter visualized under Alliance 4.7 transillumina-
tor (UVITEC Limited, Cambridge, UK).
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KatG, rpoB, rrs and eis gene amplification through
Polymerase Chain Reaction
Resistant genes to first-line drugs were amplified using
primers RTB511f (5′ TGGCACGCTGCCGGCACCTA)
and RTB 311r (5′ CGAAGCCGAACCCGAACGTC) for
katG gene. After initial denaturing at 93°C for 5 min, 3-
step cycling for 30 amplification cycles were completed
each consisting of 1 min at 95°C, 1 min at 64°C and 2 min
at 72°C. A final extension of 10 min at 72°C was applied.
For the rpoB gene the RDRSf (5′GTCGGTCATGTTCGC
GATCG) and RDRAr (5′ TCGGCCAGGTAGTCGCT
GAT) primers were used. After initial denaturing at 95°C
for 5 min, 3-step cycling for 40 amplification cycles were
completed each consisting of 1 min at 95°C, 1 min at 64°C
and 1 min at 72°C. A final extension of 10 min at 72°C was
applied. The molecular detection of resistant genes to
second line drugs was done by amplifying the DNA with
second line drugs primers; RRS2f (5′ TGCCGGGGTCA
ACTCGGAGG) and RRS2r (5′ GAACCCCTCACGGCC
TACGC) for the rrs gene. After initial denaturing at 94°C
for 4 min, 3-step cycling for 35 amplification cycles were
completed each consisting of 1 min at 94°C, 1 min at 58°C
and 2 min and 30 s at 72°C. A final extension of 10 min at
72°C was applied. Eisf1 (5′ GCCATGGGACCGGTAC
TTGC) and Eisr1 (5′ GTAGATGCCGCCCTCGCTAG)
for the eis gene was the second primer used to amplify re-
sistant genes to second line drugs with initial denaturing
at 94°C for 4 min, 3-step cycling for 35 amplification cy-
cles were completed each consisting of 1 min at 94°C,
1 min at 54°C and 2 min and 30 s at 72°C and a final ex-
tension of 10 min at 72°C.
The samples were amplified by PCR using the synthetic
oligonucleotide primers that have been mentioned above.
PCR was carried out in 25 μl tube containing 12.5 μl of
master mix with (Tris pH 8.0, MgCl2, dNTP, 1UTaq polymer-
ase), 8.5 μl water (DDW molecular grade), 1 μl of each pri-
mer and 2 μl of DNA template [14]. Mycobacterium H37RV
strain was used as a positive control and sterile water used as
a negative control. The amplified products were separated in
2% agarose gels together with 100 bp ladder (Fermentas),
applied in a separate lane. Gels were stained with ethidium
bromide and photographed on UV transiluminator.
Sequencing of KatG, rpoB, rrs and eis genes
To check for resistance and possible mutations, twelve
amplicons per gene of the amplified products were se-
quenced. DNA sequencing was performed using a Big Dye
Terminator DNA sequencing kit v3.1 (Applied Biosystems,
UK). Direct sequencing was done with 2 μL of chromo-
somal DNA, 0.25 μL of primer (10 pmol per μL), 2 μL of
Big Dye buffer and 2 μL of Big Dye. Cycle parameters in-
cluded a denaturation at 96°C for 10 s, annealing at 50°C
for 20 s, and extension at 60°C for 4 min over 30 cycles,
followed by Agencourt CleanSeq clean up. Sequences were
determined by electrophoresis with the ABI 3130xl DNA
sequencer (Applied Biosystems, UK). Editing of the se-
quences was performed using Bioedit Alignment Editor.
Cleaned sequences were sent to BLAST using the nBLAST
in NCBI (http://www.ncbi.nlm.nih.gov/); resistant genes
were categorized to resistance types by their resistance
profiles and sequence similarity [15]. The study was ap-
proved by the research ethics committee of the Goven
Mbeki Research and Development Centre, University of
Fort Hare, Record Number 2012/2013-01356. Written in-
formed consent from participants was obtained and the
confidentiality of the patients’ identities was protected.




Figure 1 Mycobacterium tuberculosis complex detection through the amplification if the MPB64 immunogenic protein. The DNA Marker
shows two bands which are the internal control band (520 bp) and the M. tuberculosis band at (190 bp). This shows how positive samples should
be. The positive control shows two bands as well, the internal control (520 bp) and an upper band corresponding to 745 bp (instead of 190 bp) which
is designed by the manufacturer to eliminate false positive resulting from cross contamination. The negative control shows only the internal control
(520 bp), negative samples shows only this band. Lane 1: DNA Marker; lane 2: Positive control; lane 3–7 DNA samples; lane 8: Negative control.
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Results and discussion
Amplification of Seeplex DNA samples results
One hundred and ninety (190) DNA samples out of the
three thousand eight hundred and ten (3810) specimens
were used in the study. This is 5% of the specimens that
were positive for MTBC. The Seeplex® MTB Nested
ACE detection assay target multi DNA regions (mpb64
and IS6110). The internal control (520 bp) is used to
identify processed samples containing substances that
may interfere with PCR amplification. The M. tuberculosis
band corresponds to 190 bp and this is the band that con-
firms that this is M. tuberculosis complex (Figure 1). The
main strength of the Seeplex® MTB Nested ACE detection
assay is that it uses multi-target PCR (IS6110 and mpb64)
for the specific detection of MTBC only; this prevents
false positive results that are caused by other mycobac-
teria. However, the assay has a weakness of not differenti-
ating amongst the different members of the MTBC. The
sample in lane 6 showed a band at 190 bp and a very faint
one at 520 bp, therefore we then re-ran a gel to be sure of
the band and we properly mixed the DNA before loading
to a 2% agarose gel and two visible bands were obtained at
190 bp and 520 bp.
From the biodata (Table 1) we observed that most of
the patients were from the black race with 84.2% (160/
190) and the rest were of the mixed race 15.8% (30/190).
We then compared our findings with the population of the
Nelson Mandela Bay Metropolitan Municipality (Port
Elizabeth) which is 1 152 115 [7]. According to Census [7],
60.1% are black African, 23.6% mixed race, 14.4% white
and 1.1% Indian/Asian. Of the population, 552 994 (48%)
are male and 599 121 (52%) are female. “Young people
(0–14 years) constitute 25, 5% of the population, youth
(15–35 years) 37,1%, adults (36–64 years) 31,4% and the
elderly (65+ years) 6%” [16].
When looking at the statistics by Census [7], black
Africans are more than any other race in this Municipality.
This results show high prevalence of MTBC amongst the
black race which could be due to the fact that these sam-
ples were collected from public clinics, where most black
people frequently visit because of the low cost. Some
mixed race people attend public clinics and some attend
private clinics and that could be one of the reasons there
was 15.8% mixed race that had MTBC. However it could
also be because of sampling bias where only samples from
eastern part of the Eastern Cape were received irrespective
of gender or race. The mixed race and black people work
together most of the time and some attend the same
schools and stay in the same location which increases the
risk of transmission of MTBC between the two races.
A fascinating observation from our results (Table 1)
was made in this study where were observed that there
are more females (56.8%) in this study that were de-
tected to have MTBC in comparison to males (43.16%)
which contradicts what other studies have reported on
[6,17]. It has been reported that in most of the world,














0–14 2 (1.05) 7 (3.68) 6 (3.160) 3 (1.58) 0
15–24 8 (4.21) 24 (12.63) 28 (14.74) 4 (2.11) 0
25–44 52 (27.4) 65 (34.21) 100 (52.6) 17 (8.95) 0
45–64 19 (10) 9 (4.74) 22 (1.58) 6 (3.16) 0
65+ 1 (0.53) 3 (1.58) 4 (2.11) 0 0
Total 82 (43.16) 108 (56.84) 160 (84.2) 30 (15.79) 0
N (%), number and percentage.
Table 2 Susceptibility and resistance profile of M. tuberculosis genotypes to first and second line anti-mycobacterium
drugs
TB resistance profiles to first line (FL) drugs TB resistance profiles to second line (SL) drugs
Parameter INH RIF STM EMB MDR ETHIO OFL CAP AMIK Pre-XDR XDR
Age N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
≤ 20 23 (12.1) 22 (11.6) 12 (6.3) 2 (1.1) 22 (11.6) 2 (1.1) 1 (0.53) 2 (1.1) 4 (2.1) 2 (1.1) 23 (12.1)
21–40 114 (60) 114 (60) 73 (38.4) 20 (10.5) 114 (60) 23 (12.1) 30 (15.8) 7 (3.6) 58 (30.5) 18 (9.4) 83 (43.7)
41–60 46 (24.2) 46 (24.2) 21 (11.1) 3 (1.58) 46 (24.2) 5 (2.63) 3 (1.6) 4 (2.1) 18 (9.5) 12 (6.3) 46 (24.2)
≥61 5 (2.6) 5 (2.6) 2 (1.1) 0 (0) 5 (2.6) 2 (1.1) 2 (1.1) 0 (0) 3 (1.6) 1 (0.53) 5 (2.6)
Total 188 (98.9) 187 (98.4) 108 (56.8) 25 (12.7) 187 (98.4) 32 (16.8) 36 (18.9) 13 (6.8) 83 (43.7) 33 (17.4) 157 (82.6)
Gender
Male 85 (43) 84 (42.6) 47 (23.5) 8 (4) 84 (42.6) 17 (8.6) 14 (7.1) 5 (2.5) 36 (18.2) 17 (8.6) 85 (38)
Female 105 (55.3) 105 (55.3) 60 (31.6) 10 (5.3) 105 (55.3) 15 (7.9) 22 (11.6) 8 (4.21) 47 (24.7) 16 (8.42) 85 (44.7)
Total 190 (100%) 189 (99.5) 107 (56.3) 18 (9.5) 189 (99.5) 32 (16.8) 36 (18.9) 13 (6.8) 83 (43.7) 33 (17.4) 157 (82.6)
INH = isoniazid, RIF = rifampicin, STM = streptomycin; EMB = ethambutol; MDR =multi-resistant drug, ETHIO = ethionimide, OFL = ofloxacin, CAP = capreomycin,
AMIK = amykacin, pre-XDR = pre-extensively drug resistant, XDR = extensively drug resistant.
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more men than women are infected by MTBC [7]. A re-
port by Census [7] gave the population of the people in
Nelson Mandela Bay Metropolitan Municipality 552 994
(48%) are male and 599 121 (52%) are female which
shows that there are more females than males in this re-
gion. However, our results concerning females being
more infected by MTBC compared to males might be
due to the fact that females care for the sick, both chil-
dren and their husbands or brothers. It can also be as a
result of selection bias where more samples for females
were chosen than males.
Nevertheless most women die due to TB [6] and this
affect woman mainly in their economically and repro-
ductively active years [6]. This was shown in our study
(Table 1) where 47% of women aged 15–44 years are the
most infected. Our results are also in agreement with a
study by Murray et al. [18] who found out that in women
aged 15–44 years in developing countries TB is the most
common cause of morbidity and mortality combined, and
it kills more women than any other infectious disease in-
cluding malaria and AIDS [18]. It was noted that the
group from 15–44 years is a sexually and economically ac-
tive age groups which could be another reason of having
more females detected with MTBC. This does not mean
that TB is contracted through sexual intercourse but it is
transmitted by having a close contact with someone in-
fected or an animal. This result (Table 1) indicates that TB
can infect any race exposed to MTBC despite their genetic
make-up and age group.
Drug susceptibility results
One hundred and ninety (100%) of the patients were
found to be resistant to at least one or more anti-TB drugs
(Table 1). Resistance to only one drug was found in all 190
patients who were infected with MTBC resistant to isonia-
zid 190 (100%) as the highest resistance while the lowest
resistant profile was observed on ethambutol with 9.5%.
Almost all the samples (99.5%) that were resistant to iso-
niazid were also resistant to rifampicin. The findings of
the study supports what other authors hypothesized which
states that rifampicin can be used as a surrogate marker
for MDR, this is due to the fact that 99.5% of rifampicin
resistant Mycobacterium tuberculosis strains are equal to
isoniazid [19-21]. Only one (0.53%) sample was suscep-
tible to rifampicin. This is a first report of high drug resist-
ant MTBC Port Elizabeth; these results are higher than
those that were reported by Green et al. [22] who reported
on 58.4% MDR-TB in the Mpumalanga Province of South
Africa.
From the resistant profiles (Table 2) we noted that
multidrug-resistant TB was identified in 189 (99.5%).
Drug resistant TB develops from inadequate treatment of
pulmonary TB [23]. Resistance to drugs used for TB treat-
ment may also be due to poor drug selection by medical
doctors [24]. Suggestion of several biological mechanisms
linking drug-resistant TB and HIV has been made [25].
Drug malabsorption in HIV-infected patients, especially ri-
fampicin and ethambutol can lead to drug resistance lead-
ing to treatment failure [23]. Malabsorption is caused by
1 2 3 4 5 6 7 8 9 10 11 12 13
100 bp ladder 
300 bp 
238 bp 
Figure 2 Amplification of the rpoB gene in DNA samples. Lane 1: 100 bp ladder; lane 2: positive control; lane 3–13: DNA isolates; lane 14:
negative control.
Figure 3 Amplification of the Kat G gene in DNA samples. Lane 1: 100 bp ladder; lane 2: positive control; lane 3–5 and 7: DNA isolates;
lane 8: negative control.
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the damage to the intestinal villi caused by HIV, Crypto-
sporidium, one of the commoner and more serious oppor-
tunistic gut infections [26-28]. Possible mechanisms
responsible for malabsorption HIV/AIDS include the im-
pact of HIV on villi specitre enzyme deficiencies in intes-
tinal mucosa, the opportunistic infections and altered
intestinal transit have all been considered but these are
mainly conjectural and effective treatments remain to be
developed [29]. Data that supports this hypothetic state-
ment has not yet been observed in humans [30]. Other
studies done in South Africa also did not find association
between HIV-infection and MDR-TB such as a retrospect-
ive study conducted in Durban, where 2.4% of 42 HIV co-
infected and 11.5% of 253 HIV negative patients had
MDR-TB [31]. In a study in Cape Town MDR-TB was
2.6% in 155 HIV negative in comparison of 32% in 93 HIV
co-infected patients [32]. In gold miners, MDR-TB rate
was 5.3% among 207 HIV co-infected and 6.5% of 218
HIV negative miners [33].
On the second line drugs resistance to capreomycin was
the lowest 13 (6.8%) and the highest was amykacin in 83
(43.7%). Pre-extensively drug tuberculosis was detected in
33 (17.4%) patients and extensively drug resistant TB was
detected in 157 patients. Thirty three isolates (17.4%) were
identified as pre-XDR and one hundred and fifty seven
isolates were identified as XDR-TB. Comparing our results
with the study by Campbell et al. [34] who reported oflox-
acin (69: 21.9%) and amykacin (1:0.3%), our values are
only high in amikacin resistance which was 43.7%. Of the
tested isolates 55 (16%) were susceptible to all the study
antibiotics and 10 (3%) were determined to be XDR-
M. tuberculosis [34]. Our results show a high drug resist-
ance of second line drugs in the Eastern Cape, South Africa.
Mutation conferring resistance to INH, RIF, CAP and KAN
drugs
After amplification with the primers that amplify the
katG and rpoB genes, 157 isolates showed positive bands
to rifampicin (rpoB gene) and 104 isolates showed posi-
tive bands to isoniazid (katG gene). The samples that
did not show any bands were properly mixed and they
were ran on 2% agarose gel again. We observed that all
190 amplicons showed bands which confer resistance to
RIF and INH drugs (Figures 2 and 3). Amplification of
the genes (rrs and eis), conferring resistance to second
line regimen was observed in 39 isolates for eis gene and
89 isolates showed positive bands to injectable drugs (rrs
gene) (Figures 4 and 5).
In our study we observed INH-resistant strains in
71.4% (100/140) with mutations at codon 315 on the an-
alyzed isolates analyzed. The katG gene encodes the cata-
lase peroxidise enzyme [35] and is present in variable
regions of the MTBC genome and contains a repetitive
DNA sequence. A study by Van Doom et al. [36] and
Bokonyte et al. [37] showed high INH-resistant strains that
had mutations on codon 315 (S to T) with St Petersburg
1 2 3 4 5 6 7 8 9 1 1 1 1
601 bp200 bp
Figure 4 Amplification of the eis gene in DNA samples. Lane1: 100 bp ladder; lane 2: positive control; lane 3–13: DNA samples; lane 14:
Negative control.
1 2 3 4 5 6 7 8 9 10 11 12
439 bp
200 bp
Figure 5 Amplification of the rrs gene in DNA samples. Lane 1: 100 bp ladder; lane 2: positive control; lane 3–10 DNA isolates; lane 12:
negative control.
Bhembe et al. BMC Infectious Diseases 2014, 14:479 Page 6 of 9
http://www.biomedcentral.com/1471-2334/14/479
of Russia (92%), Lithuania (85.7%) and Netherlands (89%).
In our study 35.7% (50/140) had an amino acid change
(S→N), this mutation was also seen in isolates from
Spain [38], while 7.1% (10/140) (T→ S) and 7.1% (10/140)
(T→N) were also observed. This amino acid changes do
not have much information reported on them. The high
percentage of mutation at codon 315 and different substi-
tutions demonstrates the importance of this codon in the
development of INH resistance among strains from Port
Elizabeth. A mutation at codon 293 seems to be rare and
not much information on it has been given. In our sam-
ples twenty mutation 14.3% (20/140) were found at this
position. We suggest that codon 293 is involved in
the resistance mechanism in this isolates. A mutation
7.1% (10/140) (R→ L) was also seen in the samples. Mu-
tations from this position have been reported before by
Haas et al. [39] from African strains. The very same muta-
tions were reported by Musser et al. [40] who suggested
an ancestral kat G (R) genotype for 127 isolates of
M. microti, M. bovis and M. africanum [39]. Before the
report of Walter et al. [41], the R mutation at position 463
was described for only M. tuberculosis [41]. In the kat G
gene region, seven different mutations were observed,
35.7% (50/140), 14.3% (20/140) and 7.1% (10/140) five
mutations (Table 3). Two isolates did not have any muta-
tions suggesting that its not only the regions of DNA that
were investigated in this study that confers resistance
to IHN.
We also observed RIF-resistant strains in 99.5% (189/
190) of the isolates with different mutations on the rpoB
gene of 140 different strains were analyzed. The results
obtained from this study were interesting; hence we ob-
served other mutations that have not been reported previ-
ously (Y42→D). In our study the prevalent mutation
among the RIF-resistant isolates was at codon 42 (21.4%)
and not much information has been published concerning
this mutations. This mutation was followed by 14.3% of
mutations on codon 52 (G→A), codons 87 (H→G); 92
(L→ S); 441 (L→ S); 450 (L→ P) and 457 (showed 7.1%
(10/140). Codon 531 is known to be a hot spot for rpoB
gene mutations [42]. This mutation is reported in most
studies, one of the studies in Taiwan reported 54.9% of mu-
tations in codon 531 [42]. These mutations (at codon 531)
were also observed in other countries such as Germany
71% [43], Italy 59% [44], Greece 56% [45], Japan 43% [46]
and Mozambique 21% [47]. There were seven different
mutations on this gene that were observed. The mutations
are highlighted in (Table 4).
The rrs gene it consist of injectable anti-TB drugs such
as amikacin (AMK), kanamycin (KAN) and capreomycin
(CAP) [48]. Proper use of injectable drugs is critical to
the effective treatment of MDR-TB and in prevention of
XDR-TB [48]. Mycobacterium culture and susceptible
testing in media either solid or liquid relies on conven-
tional diagnosis of MTBC strains [49]. This method is not
reliable for the detection of injectable drugs resistance
[49]. AMK and KAN bind to the 16S rRNA in the 30S
ribosomal subunit and inhibit protein synthesis [50] and
CAP interferes with translation and inhibits phenylalanine
synthesis in mycobacterial ribosome [51]. Mutations in
the MTBC that prevents the binding of the injectable
drugs to the targeted pathogen gene have been associated
with resistance to the three injectable drugs [52,53].
In our study among the 120 isolates sequenced, four
types of mutation patterns were observed in the rrs gene
region; S2170A, R2201G, K2202E and a deletion in pos-
ition 2207. The most observed mutation within the region
was an S→A 100% (120/120) substitution at position
2170 followed by 58.3% silent mutation (70/120) R→ R,
66.7% (80/120) of K→ E and a deletion 41.7% (5/12) at
position 2207 (Table 5). Mutations shown in the table are
more than the number of isolates that were sent for se-
quencing. This is because one isolate had more than one
mutation in it which therefore increased the number of
mutations that are seen in Table 5. Mutations associated
with injectable drug resistance are under studied in
Table 3 Frequency of mutations in katG gene codons 293, 315 and 463 in 140 INH-resistant strains of M. tuberculosis
complex
katG gene mutation positions
N293→G S293→G S315→ T S315→N T315→N T315→ S R 463→ L
No. of strains (%) 10 (7.1%) 10 (7.1%) 20 (14.3%) 50 (35.7%) 10 (7.1%) 10 (7.1%) 10 (7.1%)
N = Asparagine; G = Glycine; S = Serine; T = Threonine; R = Arginine; L = Leucine.
Table 4 Frequency of mutations in rpoB gene codons 42, 52, 87, 92, 441, 450 and 457 in 140 RIF-resistant strains of
M. tuberculosis complex
rpoB gene mutation positions
Y42→D G52→ A H87→G L92→ S V441→ G L450→ S L 457→ P
No. of strains (%) 30 (21.4%) 20 (14.3%) 10 (7.1%) 10 (7.1%) 10 (7.1%) 10 (7.1%) 10 (7.1%)
Y = Tyrosine; D = Aspartic; G = Glycine; A = Alanine; H = Histidine; L = Leucine; S = Serine; V = Valine; P = Proline.
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comparison with mutations associated with first-line drugs
[54]. Most studies have reported on C1143G and T1521C
in the rrs gene. In our study, these mutations were not
found in the isolates studied and have not been described
as conferring resistance [55]. Studies by Maus et al. [56]
and Krüüner et al. [57] has reported on mutations in the
500 rrs region A514C and C417T, even these mutations
were not found in our study.
Conclusions
The results obtained from this study show a high prevalence
of MTBC among Eastern Cape population. Of noteworthy
is the fact that women at their reproductive years are
mostly infected and this could lead to a vicious cycle,
hence women are exposed to a lot of people. The study
also revealed a high prevalence of MDR amongst the Eastern
Cape population.
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